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Abstract
Background: Hypothyroidism is a prevalent endocrine condition. Individuals with this disease are commonly
managed through supplementation with synthetic thyroid hormone, with the aim of alleviating symptoms and
restoring normal thyroid stimulating hormone levels. Generally this management strategy is effective and well
tolerated. However, there is research to suggest that a significant proportion of hypothyroid sufferers are being
inadequately managed. Furthermore, hypothyroid patients are more likely to have a decreased sense of well-being
and more commonly experience constitutional and neuropsychiatric complaints, even with pharmacological
intervention.
The current management of hypothyroidism follows a biomedical model. Little consideration has been given to a
biopsychosocial approach to this condition. Within the chiropractic profession there is growing support for the use
of a biopsychosocial-based intervention called Neuro-Emotional Technique (NET) for this population.
Methods/Design: A placebo-controlled, single-blinded, randomised clinical pilot-trial has been designed to assess
the influence of Neuro-Emotional Technique on a population with primary overt hypothyroidism. A sample of 102
adults (≥18 years) who meet the inclusion criteria will be randomised to either a treatment group or a placebo
group. Each group will receive ten treatments (NET or placebo) over a six week period, and will be monitored for
six months. The primary outcome will involve the measurement of depression using the Depression, Anxiety and
Stress Scale (DASS). The secondary outcome measures to be used are; serum thyroid stimulating hormone, serum
free-thyroxine, serum free-triiodothyronine, serum thyroid peroxidase auto-antibodies, serum thyroglobulin auto-
antibodies as well as the measurement of functional health and well-being using the Short-Form-36 Version 2. The
emotional states of anxiety and stress will be measured using the DASS. Self-measurement of basal heart rate and
basal temperature will also be included among the secondary outcome measures. The primary and secondary
measures will be obtained at commencement, six weeks and six months. Measures of basal heart rate and basal
temperature will be obtained daily for the six month trial period, with recording to commence one week prior to
the intervention.
Discussion: The study will provide information on the influence of NET when added to existing management
regimens in individuals with primary overt hypothyroidism.
Trial Registration: ANZCTR Number: 12607000040460
Background
Hypothyroidism is a frequently encountered clinical
condition and is the most common cause of pathological
hormone deficiency. Hypothyroidism is classified as
either congenital or acquired, based on the time of
onset. The condition is further categorised based on
level of endocrine dysfunction and severity. Primary
hypothyroidism follows a dysfunction of the thyroid
gland itself, whereas secondary hypothyroidism results
from failure in the machinery or mechanisms peripheral
to the thyroid gland (eg. hypopituitarism). Overt
hypothyroidism defines the clinical manifestation of the
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to the subclinical variants of the disease [1]. The diagno-
sis of hypothyroidism is based on a thorough history,
clinical findings and laboratory analysis. Although a defi-
cit in thyroid hormones and their resultant action has a
varying systemic influence, individuals with overt
hypothyroidism frequently present with fatigue, depres-
sion, cold intolerance, weight gain, hoarseness, dry skin,
bradycardia, constipation and slowed mental processing
[2]. Laboratory testing in individuals with primary overt
hypothyroidism typically depicts an elevated serum thyr-
oid stimulating hormone (TSH) level, and a decrease
in serum free-thyroxine (FT4) levels [3]. One of the
major causes of acquired hypothyroidism is chronic
autoimmune thyroiditis (Hashimoto’s Disease) in which
laboratory testing may reveal auto-antibodies to the
thyroglobulin protein (Anti-Tg), and the thyroid peroxi-
dase enzyme (Anti-TPO) [4,5].
The gold standard treatment for individuals with
hypothyroidism is supplementation using a synthetic ver-
sion (Levothyroxine Sodium) of the thyroid hormone -
thyroxine [1]. Patients are typically given a supplemental
dose (1.8 μg/kg in adults) of levothyroxine sodium daily
for an indefinite period of time, with the aim of improv-
ing the function of the patient and restoring appropriate
TSH levels [1]. Once an appropriate dose has been
established, thyroid hormones levels are monitored every
6-12 months to ensure the adequacy of treatment [6].
Treatment dose may be altered based on a number of
different variables; treatment efficacy; comorbid-illness;
significant alterations to weight; oestrogen use; preg-
nancy; age [1,7].
The treatment of individuals with hypothyroidism
typically follows a biomedical paradigm. There are
clearly defined biochemical boundaries for what consti-
tutes the clinical manifestation of hypothyroidism and
standard algorithms to guide the commencement and
progression of treatment. Several studies however have
reported inadequate treatment (as determined by thyr-
oid blood markers) in a significant proportion (20%) of
individuals with ‘managed’ hypothyroidism [8,9]. Sarava-
nan et al report that substantial numbers of hypothyroid
sufferers continue to experience the plethora of
hypothyroid symptoms despite demonstrating hormone
levels within reference ranges [10].
Whybrow et al state that almost 100% of severe
hypothyroid sufferers are found to have significant con-
current depression [11]. Grozinsky-Glasberg et al state
that hypothyroid patients are more likely to have a
decreased sense of well-being and more commonly
experience constitutional and neuropsychiatric com-
plaints as compared to euthyroid individuals [12]. Prac-
titioners must take care when initiating treatment for
hypothyroidism in certain populations (ischemic heart
disease, adrenal cortical insufficiency) and be mindful of
avoiding adverse drug interactions [1].
After an exhaustive search of the medical literature it
would appear that little consideration has been given to
the concept of a biopsychosocial-based management
approach to this condition. Within the chiropractic pro-
fession there are anecdotal reports and case studies [13]
to suggest that a biopsychosocial-based treatment
approach may be applicable to hypothyroidism. This
manuscript has been compiled to outline the methodol-
ogy for a randomised-controlled clinical study investi-
gating a biopsychosocial approach to primary overt
hypothyroidism that adheres to the CONSORT [14]
checklist in its design.
Methods
The objectives of this research are described below:
1) To determine whether the addition of NET to con-
current management regimens can improve clinical out-
comes in a sample of individuals with primary overt
hypothyroidism. For Example, reducing the severity of
depression scores at six weeks and six months; 2) To
determine the short and medium term responses to
NET via changes to the primary and secondary out-
comes in this sample.
Design
An ethics approved, registered, prospective, multivariate,
placebo-controlled single-blinded, randomised, clinical
pilot-trial.
Ethics Review
The pilot-trial protocol and associated materials have
been reviewed and approved by the Macquarie Univer-
sity Human Ethics Committee (Sydney, Australia).
Settings
Eleven private practices located in Sydney, Australia.
The private practices are situated in ten different sub-
u r b sa r o u n dt h eS y d n e yr e g i o n .T h ed i s t r i b u t i o no f
practice locations has been chosen in an attempt to gen-
e r a t eas a m p l et h a tw i l lb er e f l e c t i v eo ft h eg e n e r a l
population of Sydney.
Practitioners
Twelve practitioners (five female, seven male) have
agreed to donate their time to administer the treatments
to the trial participants. The practitioner group consists
of nine registered chiropractors, two psychologists, and
one psychotherapist. Teachers of NET stipulate that all
practitioners must hold a doctorate or master’sl e v e l
degree in the healing arts before they may learn NET.
All of the care providers have a minimum of two years
experience using NET, and have attained ‘NET
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proficiency recognised within the technique system).
These practitioners have been chosen because of their
expertise in the NET field. The chief investigator (BTB)
will conduct an individual training session for each
practitioner involved with the trial. In addition to the
training sessions, practitioners will be given a trial refer-
ence booklet that details the specifics of the trial. Practi-
tioners will also have phone and email access to the
chief investigator at all times in the event that further
questions surface following the initial briefing.
Participants
Participants will respond via a toll-free number to
advertisements placed in a variety of different media
including; newspapers, magazines, websites, and flyers.
An attempt will be made to disseminate hardcopy
advertisements in a variety of geographical locations
around Sydney. The advertisements will call for partici-
pation in a research project examining the influence of
a new treatment for hypothyroidism (See Additional File
1). Respondents will be screened over the phone by the
chief investigator to determine their eligibility to partici-
pate based on a set of inclusion and exclusion criteria.
Eligible participants will then be sent a trial information
booklet that explains the details of the trial. Participants
will be given an opportunity to read through the trial
information and make an informed choice as to whether
or not they wish to participate in the research. One
week after receiving the trial information booklet, poten-
tial participants will receive a follow-up telephone call
from the chief investigator to ascertain their desire to
participate, and to answer any further questions. From
this point, willing participants will be sent the salient
information to begin their involvement in the trial.
Informed Consent
In addition to the trial information booklet, all partici-
pants will be issued with a copy of the informed consent
form. The consent form will detail the names of the
individuals involved with the study: chief investigator;
supervisors/co-investigators; practitioners. Participants
will also be informed that the research is being con-
ducted by the Department of Chiropractic at Macquarie
University. A brief description of the study protocols
will also provided; duration of the study; outcome mea-
sures employed; adverse reactions to treatment and the
associated back-up counselling services; ethics approval
and contact details of the ethics officer; the right to
cease participation at any time; methods for dissemina-
tion of results; complaint procedures and privacy policy.
Participants will not be asked to alter or cease any exist-
ing treatment regimens. Any concurrent treatment regi-
mens will be recorded.
Sample
The study population will consist of at least 102 indivi-
duals with a diagnosis of overt primary hypothyroidism,
who are undergoing a variety of management strategies
(including no treatment), from Sydney, Australia. A jus-
tification for the sample size is provided later.
Inclusion Criteria
For inclusion, participants will have to meet several cri-
teria: 18 years of age or over; and previous diagnosis of
primary overt hypothyroidism by a qualified medical
practitioner or specialist. If respondents are being medi-
cated for their thyroid condition, it will be required that
they be on a stable dose of medication for at least six
months before entering the trial. Any alteration to a
participant’s medication levels during the trial will be
recorded. Respondents who do not meet the inclusion
criteria or who meet the exclusion criteria will be
excluded from the study.
Exclusion Criteria
The exclusion criteria will comprise: less than 18 years
of age; absent diagnosis of hypothyroidism; iatrogenic
hypothyroidism; recent diagnosis of hypothyroidism
(within the last six months); presence of co-morbid ill-
ness that can impair thyroid hormone production and
metabolism; use of medications that can impair thyroid
hormone production and metabolism; history of head or
neck surgery/radiotherapy; history of significant head
trauma; serious co-morbid illness (e.g. cancer); serious
co-morbid mental illness (e.g. psychosis); pregnancy or
desire to conceive within the study period; physical or
mental disabilities that would prevent participants inter-
acting physically and verbally with the care provider
during the intervention.
Withdrawals and Protocol Violations
All withdrawals and protocol violations will be recorded.
As part of the trial information booklet and informed con-
sent form, participants will be assured that they may with-
draw their participation at any time without consequence
or explanation. All participants who cease participation
will be followed up to confirm their withdrawal. Partici-
pants will be given the option to comment on the reason
for their withdrawal. If a participant does declare their rea-
son for withdrawal, this will be recorded. Any alteration to
the patient’s health status or existing management regi-
mens during the trial period will be recorded and factored
into the final analysis and interpretation. This will include
changes in medication/type of medication.
Adverse Reactions
All adverse reactions will be recorded. In the published
literature on NET there have been no documented
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participants will be exposed to any unnecessary risks.
Due to the nature of the NET procedure/study proto-
col there is potential for a mild uncomfortable recall of
past events in the NET treatment group. There is also
potential for some mild focal soreness following the
tapping procedures applied in both the NET and the
placebo groups. Any participant experiencing anything
more than a mild discomfort/soreness, or becoming
emotionally distressed, will have their participation in
the study reviewed and their potential for withdrawal
assessed. In the case of any adverse reaction, the rele-
vant help will be rendered to the participant at no
charge. The primary health care provider will also be
notified in the event of any significant changes/revela-
tions in a participant’s health status that are witnessed
prior to commencement or during a participant’s
involvement in the trial.
Randomisation and treatment allocation
Eligible participants will be randomly allocated to either
the NET treatment group or the placebo (sham inter-
vention) group. A random sequence generator will be
used to produce a random sequence (1-200) with no
repeats. These numbers will be recorded on individual
pieces of paper and placed into envelopes which will
then sealed and shuffled. After the participant has com-
pleted their initial blood test, the chief investigator will
select an envelope for that participant. Participants allo-
cated an even number will be assigned to the treatment
group, and those receiving an odd number will be
assigned to the placebo group.
Blinding
The allocation of individual participants to treatment
groups will be concealed to the chief investigator up
until the point of a participant commencing treatment.
I n d i v i d u a lp a r t i c i p a n t sw i l ln o tb et o l dt h e i rg r o u pa l l o -
cation until the completion of their involvement in the
trial. All participants allocated to the placebo interven-
tion group will have the opportunity to receive the NET
treatment free of charge at the completion of their
initial participation. No other incentives will be given
for a participant’s involvement or follow-up.
Any primary care providers (e.g. endocrinologist) will
be blinded to the participant’s group allocation. As the
practitioners involved in the study will be performing
both the NET treatment and the placebo intervention, it
will be necessary for the group allocation to be disclosed
to these practitioners. Practitioners will be instructed to
perform the placebo with the same gusto as the NET
treatment. The treating practitioners will have no pre-
vious role in the diagnosis or management of the parti-
cipant’s thyroid condition.
Group allocation will be concealed from the pathology
company involved in the collection and analysis of the
serum outcome measures. Statisticians involved in the
analysis of the trial data will be blinded to group
allocation.
Protocol
Participants will be randomly allocated to either a treat-
ment group (NET) or a placebo group. Both groups will
receive ten interventions (either NET or placebo) during
the initial 6 weeks of the trial period. Two interventions
will be administered in the first four weeks followed by
one intervention per week in the remaining two weeks.
NET Protocol
Neuro-Emotional Technique was developed by Walker
[21] in 1985, and can be summarised as a 15-step,
multi-modal intervention that incorporates principles
from several health disciplines, including; chiropractic,
biology, cognitive behavioural psychology, and Tradi-
tional Chinese Medicine (TCM)[22]. A brief description
of the NET procedure is described below. It is impor-
tant to note that the procedure is based on many differ-
ent theories. Some of these theories have been well
researched, while others have not undergone the same
scientific scrutiny.
The NET procedure is specifically designed to detect
and remove a specific type pathophysiological/syndromal
pattern called a Neuro Emotional Complex (NEC).
Walker postulates that the presence of NECs has a
negative influence on an individual’sp h y s i o l o g y ,a n d
that by removing NECs using NET, physiological home-
ostasis may be promoted [21].
W a l k e rd e f i n e st h eN E Ca sasubjective maladaption
syndrome adopted by the organism in response to a real
or perceived threat to any aspect of its survival [21].
Walker states that the NEC/syndromal pattern will con-
tain the aspects listed below:
1)A facilitated or inhibited muscle; 2) A specific active
Meridian Access Point (MAP); 3)An imbalance in a
meridian, and an active pulse point or MAP point; 4)
A specific emotion; 5) A cathected and often recallable
memory picture (Snap Shot) of a past significant emo-
tional event; 6) A conditioned response with a resistance
to extinction, and a predisposition for stimulus generali-
zation; 7) A vulnerability to suppression, repetition-com-
pulsion and reaggravation/restimulation causing a
cyclical reinforcement; and 8) A specific subluxation or
sequence of spinal subluxations.
The protocol uses manual muscle testing (MMT) to
aid the practitioner in finding and removing NECs. A
muscle test in which the individual is unable to with-
stand a standardised test pressure is termed an inhib-
ited/weak (w) test. A muscle test in which an individual
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from the practitioner is termed a facilitated/strong (s)
test [21]. Strong and weak test outcomes are used to
provide feedback for the practitioner throughout the
protocol. The specific steps of the protocol and the
muscle testing outcomes at the various steps are out-
lined in the appendix (See Additional File 2) [21].
There are two methods used in NET to detect the
presence of an NEC. The two types are defined by
Walker as a Mind-Entry (ME) and a Body-Entry (BE).
The ME is used to detect the presence of an NEC by
having the patient either think of a situation/memory/
feeling or by verbalising specific statements [21,23]. The
BE method of detecting an NEC involves having the
patient or practitioner touch specific cutaneous areas on
the body recognised in TCM to be related to the pre-
senting condition. NET is based on the notion that
there will be demonstrable changes in a patient’sp h y -
siology when a salient ME or BE is employed. Manual
muscle testing (MMT) is used to demonstrate the phy-
siological change associated with the NEC [21]. For con-
venience, the anterior deltoid muscle test is most
commonly used during the NET procedure [21].
Walker states that NET engages the energetic system
of the body as described by TCM. In TCM, it is thought
that there are 12 main channels throughout the body
that carry vital energy - termed chi. These channels are
called meridians. Disruption to the flow of chi along a
meridian channels is believed to result in disease and ill
health [24]. It is postulated that elements of the NEC
are stored within this energetic network. Walker opines
that an NEC stored within the meridian system can be
accessed via cutaneous points associated with the meri-
dians (See Additional File 3 &4) [21] and MMT [21].
According to the Five Element Theory of TCM, each
of the meridians is associated with specific emotions.
For example, the liver meridian is said to be associated
with the emotion of Anger [25]. An exaggerated experi-
ence of emotion (either too much, too little, or pro-
longed experience of a specific emotion) can cause
disruption to the free flow of chi through the meridians.
The normal experience of emotion is not pathological,
but extremes of emotion are thought to cause dishar-
mony within the meridian system [24,25]. Walker and
others have expanded upon this concept and created
tables to which NET practitioners can refer to during
the NET protocol (See Additional File 5) [21]. It is
thought that NECs are created during times (past or
present) in which a person is experiencing physiological
or meridian deficit [21].
T h eN E Tp r o c e d u r ei st h e r e f o r ed e s i g n e dt of i n d
NECs that are purported to be having a negative influ-
ence on an individual’s physiological and energetic sys-
tem. The energetic imbalance accompanying the NEC
will have a related emotion and a recallable memory
picture/snap shot that is associated with that emotion.
Using the NET protocol in combination with MMT, the
specific emotion and its associated snap shot are
detected.
It is thought that the NEC may fail to resolve under
normal circumstances and can become a conditioned
response that is subject to restimulation/reaggravation
in reaction to a variety of different stimuli. For this rea-
son, NET is thought to aid in the extinction of classi-
cally conditioned responses to traumatic emotional
stimuli [18].
Walker states that there will be specific spinal regions
that will require treatment for each type of meridian
imbalance (See Additional File 5).
Once an appropriate BE or ME has been found, a spe-
cific meridian imbalance, a specific emotion, and a
recallable snap shot have been displayed, a practitioner
can proceed with the corrective phase of the technique.
The corrective procedure involves having the individual
think of the original snap shot and the associated emo-
tion, while at the same time holding the corresponding
MAP point (See Additional File 4)[21]. The practitioner
then applies a light, bilateral tapping to specific spinal
regions on breathing [21].
The original snap shot and the original BE or ME are
then tested to assess the adequacy of the treatment.
During the intervention phase, the trial practitioners
will seek to find and remove any NECs that may be pre-
sent in the trial participants using NET.
It is important to note that the version of NET to be
used in this study (12-step protocol) does not represent
the NET system in its entirety. The 12 Step protocol
utilises Steps 1-11, and Step 15. The originators of NET
champion the combined use of manual therapy, nutri-
tional supplementation and homeopathic treatment in
addition to addressing the psychosocial aspects of a
patient’s presentation [21]. For research purposes, the
initial three aspects mentioned above (manual therapy,
nutrition, and homeopathy) and steps 12-14 of the NET
protocol will be omitted to limit the number of con-
founding variables, and ensure a more accurate interpre-
tation of the results. The protocol to be used in this
research will be similar to that employed in previous
research papers describing NET as a treatment modality
[16,26-31]. Karpouzis et al published a similar protocol
for the use of NET for Attention Deficit Hyperactivity
Disorder in an open access journal in 2009 [16].
Placebo Protocol
The placebo protocol will align clearly with the NET
protocol however the purported therapeutic components
of the NET procedure will be removed and replaced
with innocuous steps (See Additional File 6.)
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The standard guidelines for the assessment of indivi-
duals with thyroid dysfunction will be used by the pri-
mary care providers to establish the diagnosis of
hypothyroidism [1]. The primary and secondary out-
come measures (DASS, SF-36v2 and Serum Measures)
will be applied pre-intervention to obtain baseline data,
then reapplied at six weeks (post-intervention) and six
months (study conclusion). Measurement of basal heart
rate and basal temperature will be applied for each day
of the six month study period, and will commence one
week prior to the research intervention.
Primary Outcome Measures
Significant proportions of individuals with ‘managed’
hypothyroidism continue to experience many of the
symptoms associated with the overt, untreated version
of the condition [1]. Depression is a common symptom
associated with primary overt hypothyroidism [1].
Hypothyroid patients are more likely to experience con-
stitutional and neuropsychiatric complaints as compared
to euthyroid individuals [12]. For this reason, the pri-
mary outcome will involve the measurement of Depres-
sion using of the Depression Anxiety Stress Scale
(DASS). The DASS is an instrument for measuring the
negative states of depression, anxiety and stress. It is
constructed of three self-report scales that enable
researchers and clinicians to more concisely define,
understand and measure these three clinical states. Each
of the three scales contains 14 items that assess different
aspects of depression, anxiety and stress [32].
The questionnaire is used to determine negative
emotional states versus negative emotional traits. The
DASS is based on a dimensional concept of psychologi-
cal disorder. For this reason, the DASS is not used to
allocate patients to specific diagnostic categories. This
concept is different to other classificatory systems such
as the Diagnostic and Statistical Manual of Mental
Disorders (DSM) and International Classification of
Diseases (ICD).
All items are rated on a four-point Likert scale from
0 - 3. Scores are determined according to how often
particular symptoms were experienced in the past week,
with high scores indicating a higher frequency of symp-
toms. Depression represents a sum of scores from 14
items within the DASS pertaining to depression [32].
States of dysphoria, hopelessness, devaluation of life,
self-deprecation, anhedonia, inertia and a lack of interest
and involvement are assessed by the ‘depression’ specific
questions within the DASS. Normative data for the
Depression scale of the DASS describes a mean of 6.34
with a standard deviation of 6.97. Clinically, depression
scores between 0-9 are considered normal. Scores of
10-13 and 14-20 indicate mild and moderate states of
depression respectively. Severe and extreme states of
depression are defined by scores between 21-27 and 28+
respectively [32].
The DASS questionnaire will be issued to each partici-
pant at the specified times; study commencement, six-
weeks and six-months. The results will be collected and
forwarded to the chief investigator for compilation
and scoring using relevant scoring algorithms and
software [32].
Improvements in the negative emotional state of
depression will be represented by decreased scores by
respondents at 6 weeks and at 6 months. The associated
anxiety and stress scores from the DASS will be
included in the secondary outcome measures.
Secondary Outcome Measures
The secondary outcome measures (from serum analy-
sis) are listed in Table 1. All blood collection and ana-
lysis will be performed by the commercial pathology
laboratory DHM. The pathology company DHM pro-
vides pathology services to general practitioners, medi-
cal specialists, nursing homes, private hospitals and
researchers [33].
Participants will be issued with a blood sample request
form that can be used at any DHM collection centre.
Blood samples will be obtained at the beginning of the
trial, then again at the six week and six month points.
Participants will be instructed to provide a blood sample
that will be used to measure a variety of thyroid related
indicators (See Table 1). There will be no specification
regarding timing or fasting for the sample collection.
The initial blood sample will completed one week prior
to the first treatment in both groups. Blood samples will
be spun in gel tubes at the collection centre before
being couriered in cold storage to the central DHM
laboratory for analysis. At the central laboratory, the
ARCHITECT® assay kits (Chemiluminescent Microparti-
cle Immunoassay) will be used to measure the TSH,
FT3, FT4 in the serum samples (Abbott Laboratories,
Abbott Park, IL, USA). Immulite® 2500 will be used to
quantify levels of anti-thyroid peroxidase antibodies and
auto-antibodies to thyroglobulin in serum. The Immu-
lite® 2500 method involves a solid-phase, enzyme
labelled, chemiluminescent sequential immunometric
assay (Siemens, Los Angeles, CA, USA). All results will
Table 1 Serum Secondary Outcome Measures
Test Name Abbreviation Reference Range
Thyroid Stimulating Hormone TSH 0.40 – 4.00 mU/L
Free Thyroxine FT4 9.0 – 19 pmol/L
Free Triiodothyronine FT3 2.6 – 6.0 pmol/L
Thyroglobulin auto-antibodies Anti-Tg 0 – 80 IU/ml
Thyroid Peroxidase auto-antibodies Anti-TPO 0 – 120 IU/L
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compilation and analysis.
It is anticipated that the majority of participants will
be receiving treatment in the form of L-Thyroxine sup-
plementation. For this reason, serum measures of TSH,
serum FT4, serum FT3 should fall within normal refer-
ence ranges (See Table 1) provided there are no major
alterations to this existing treatment strategy. In ade-
quately treated participants, the addition of the experi-
mental intervention should not influence serum thyroid
hormone levels. However, in individuals who are not
being medicated, or in individuals who are being under-
treated upon entry into the trial, a decrease in TSH
measurements and an increase in FT4 and FT3 mea-
surements may be expected during the course of the
trial.
In individuals who are being over-treated, elevated
FT4 and FT3 levels and decreased TSH measurements
will be demonstrated at baseline. It is expected that
there will be no change in the serum measures in this
subgroup.
It is unclear how the autoimmune markers will
respond to the addition of NET to any existing treat-
ment regimens.
In addition to the serum measures, participants will
fill out the SF-36v2 and the additional items (anxiety
and stress) of the DASS.
The SF-36v2 health survey is a questionnaire used to
assess outcomes in eight different domains: role limita-
tions because of physical or emotional problems, physi-
cal and social functioning, bodily pain, perception of
mental and general health, and vitality [34].
Improvements in functional health and well-being as
measured by the SF-36v2 will be depicted by increased
scores by the respondents at six weeks and at six
months. Deterioration in functional health and well-
being will be revealed by a decrease in SF-36v2 scores.
Two additional secondary outcome measures are to be
completed and recorded by participants at home for
each day of the six month trial period are listed below:
Basal Heart Rate (BHR)
Basal Temperature (BT)
After signing up to take part in the trial, participants
will be given a home diary, digital thermometer and
instructions on how to record their BHR and BT. Parti-
cipants will be instructed to make an effort to perform
these measurements at the same time each day, and ide-
ally before getting out of bed in the morning. For BHR
measurements, participants will be instructed to find
their radial pulse and then record the number of beats
that occur in one minute and record this figure in the
diary provided.
Due to the chronotropic effect of the thyroid hor-
mones on heart rate, untreated or undertreated indivi-
duals will demonstrate lower heart rates at baseline. It is
anticipated that if NET therapy has a positive influence,
there may be a trend over time toward slight increases
in heart rate.
Basal temperature recording will be performed using a
digital thermometer placed under the axilla. The ther-
mometer will be placed under the axilla for approxi-
mately two minutes and the resultant temperature
reading recorded.
Due to the thermogenic action of thyroid hormones, it
is hypothesised that unmedicated or under-treated parti-
cipants will experience an increase over time in basal
temperature that may approach normal ranges of basal
temperature (35.5 - 37.0°C) with the addition of NET
treatment [35]. Adequately treated individuals should
display normal basal temperatures at baseline that
remain unperturbed by any additional treatment.
The secondary measures of basal heart rate and tem-
perature measurement to be employed in this research
study are commonly used by thyroid specialists as a
crude measure of thyroid performance that is adjunctive
to the hormone assays [36-38].
The recording of BHR and BT will begin one week
prior to the initial intervention and continue for each
day of the clinical trial.
Power analysis and sample size justification
A (one-sided) power analysis indicated 51 subjects per
group will yield an 80% chance of detecting a decrease
in depression scores of at least four points in treatment
compared to control using a standard deviation of eight
based on simulation. Clinically, a four point reduction in
depression scores, as defined by the DASS, would repre-
sent a meaningful reduction in depressive states. A four
point decrease may indicate that an individual has gone
from expressing moderate to mild states of depression
or mild to normal expression of depressive states [32].
Statistical Analysis
Two-sample t-tests will be used to compare change
from baseline for NET treatment versus control at each
of six weeks and six months for the primary outcome
measure. Linear mixed-effects models will be used
examine change over time in the treatment and placebo
groups for the basal temperature and basal heart rate
groups as well as the other secondary outcome mea-
sures. A significance level of 5% will be used throughout
the analysis. Because the analyses will be seen as
hypothesis generating, no adjustment for multiple test-
ing will be used. The R software program [39] will be
used to conduct the analyses. Complete case analysis
will be employed for participants who strictly followed
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Page 7 of 9the trial protocol. Sensitivity analysis will be used for
withdrawals, missing data and participants who violate
the study protocol eg. changes in medication during the
study period. This will be done using imputation techni-
ques including last value carried forward, and multiple
imputation.
Discussion
We have presented the design and protocol for a pla-
cebo-controlled, single-blinded RCT that will investigate
the influence of a biopsychosocial-based treatment
approach for primary overt hypothyroidism. The partici-
pants of this study will have NET treatment added to
any existing management regimens. Anecdotal evidence
from within the chiropractic profession suggests that
NET treatment may be of benefit for individuals with
hypothyroidism. Completion of this trial will help to
describe the influence of NET treatment when com-
bined with any existing management strategies for indi-
viduals with primary overt hypothyroidism.
Status of the trial and expected achievements
Start date: September 2006; Finish date of recruitment:
March 2010; Finish date of follow-up: September 2010;
Dissemination of results: Jan 2011.
Additional material
Additional file 1: Sample of an advertisement used to recruit
participants for the clinical pilot-trial.
Additional file 2: 15 steps of the NET protocol.
Additional file 3: Pulse points used in the NET protocol.
Additional file 4: Meridian Access Points used in the NET protocol.
Additional file 5: Simplified NET master chart used in the NET
protocol.
Additional file 6: Placebo protocol used in the pilot trial.
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